Serum metabolomic signatures of fatty acid oxidation defects differentiate host-response subphenotypes of acute respiratory distress syndrome

Table 5 Relative metabolite levels in survivors, non-survivors, and vasopressor-dependent patients with acute respiratory failure within the cohort

	Survivors (N = 111)	Non-survivors (N = 39)	P-value	No Vasopressors (N = 72)	Vasopressors (N = 78)	P-value
Acetylcarnitine [Median, IQR]	0.83 [0.49, 1.31]	1.07 [0.67, 1.37]	0.066	0.79 [0.51, 1.13]	1.04 [0.52, 1.44]	0.11

	Survivors (N = 98)	Non-survivors (N = 32)	P-value	No Vasopressors (N = 60)	Vasopressors (N = 70)	P-value
Octanoylcarnitine [Median, IQR]	0.19 [0.11, 0.35]	0.24 [0.13, 0.35]	0.28	0.15 [0.075, 0.28]	0.29 [0.16, 0.44]	0.0001

	Survivors (N = 111)	Non-survivors (N = 39)	P-value	No Vasopressors (N = 72)	Vasopressors (N = 78)	P-value
3-Methylhistidine [Median, IQR]	0.17 [0.095, 0.36]	0.32 [0.16, 0.55]	0.0018	0.17 [0.095, 0.33]	0.21 [0.13, 0.51]	0.028

Relative acetylcarnitine, octanoylcarnitine, and 3-methylhistidine levels (peak area ratio of analyte/internal standard) are shown among survivors, non-survivors, and patients who did or did not require vasopressors within seven days of study enrollment. Pairwise comparisons between groups were analyzed by the Mann–Whitney U test with P-values shown for each comparison

ISSN: 1465-993X